Skip to content

Agile Therapeutics, Inc.: 10-K filed 2015-03-26

What Agile Therapeutics, Inc. reported in its annual report filed 2015-03-26 (fiscal FY 2014): 28 published measures, 97 facts as tagged in accession 0001047469-15-002798.

This filing

Form
10-K (annual report)
Filed
2015-03-26
Fiscal period
fiscal FY 2014
Accession
0001047469-15-002798 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Agile Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-12-3154,826,226USD
At 2013-12-3114,405,136USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-12-3136,005,947USD
At 2013-12-31-71,441,572USD
At 2012-12-31-58,608,415USD
At 2011-12-31-36,013,742USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-12-3140,182,141USD
At 2013-12-312,119,646USD
At 2012-12-3120,013,754USD
At 2011-12-319,562,017USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-12-31-16,077,468USD365
2013-01-01 to 2013-12-31-14,320,620USD365
2012-01-01 to 2012-12-31-23,260,127USD366

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2014-01-01 to 2014-12-3195,739USD365
2013-01-01 to 2013-12-314,945,379USD365
2012-01-01 to 2012-12-316,692,981USD366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-12-31-134,391,851USD
At 2013-12-31-118,314,383USD

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2014-10-01 to 2014-12-31-0.37USD/shares92
2014-07-01 to 2014-09-30-0.34USD/shares92
2014-04-01 to 2014-06-30-0.46USD/shares91
2014-01-01 to 2014-03-310.1USD/shares90
2013-10-01 to 2013-12-31-45.68USD/shares92
2013-07-01 to 2013-09-30-71.67USD/shares92
2013-04-01 to 2013-06-30-70.29USD/shares91
2013-01-01 to 2013-03-31-109.18USD/shares90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2014-10-01 to 2014-12-31-0.37USD/shares92
2014-07-01 to 2014-09-30-0.34USD/shares92
2014-04-01 to 2014-06-30-0.46USD/shares91
2014-01-01 to 2014-03-310.01USD/shares90
2013-10-01 to 2013-12-31-45.68USD/shares92
2013-07-01 to 2013-09-30-71.67USD/shares92
2013-04-01 to 2013-06-30-70.29USD/shares91
2013-01-01 to 2013-03-31-109.18USD/shares90

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2014-01-01 to 2014-12-31-3,652,485USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-12-3112,046,267USD
At 2013-12-3111,963,079USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2014-01-01 to 2014-12-311,380,713USD365
2013-01-01 to 2013-12-311,337,857USD365
2012-01-01 to 2012-12-31665,454USD366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-12-31-18,515,216USD365
2013-01-01 to 2013-12-31-12,728,377USD365
2012-01-01 to 2012-12-31-23,316,851USD366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-12-3140,985,916USD
At 2013-12-312,266,350USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2014-01-01 to 2014-12-311,565,730USD365
2013-01-01 to 2013-12-311,512,911USD365
2012-01-01 to 2012-12-31140,051USD366

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-12-318,992,521USD
At 2013-12-316,844,503USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2014-12-312,631,217USD
At 2013-12-31715,454USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2014-10-01 to 2014-12-316,523,996USD92
2014-01-01 to 2014-12-3118,515,216USD365
2014-07-01 to 2014-09-306,048,884USD92
2014-04-01 to 2014-06-303,494,710USD91
2014-01-01 to 2014-03-312,447,626USD90
2013-10-01 to 2013-12-311,929,557USD92
2013-01-01 to 2013-12-3112,728,377USD365
2013-07-01 to 2013-09-303,321,389USD92
2013-04-01 to 2013-06-303,249,070USD91
2013-01-01 to 2013-03-314,228,361USD90
2012-01-01 to 2012-12-3123,316,851USD366

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-01-01 to 2014-12-3113,364,704USD365
2013-01-01 to 2013-12-319,154,484USD365
2012-01-01 to 2012-12-3117,386,961USD366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-12-3118,634,872shares
At 2013-12-31103,536shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-12-31170,395,934USD
At 2013-12-3146,872,801USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2014-12-3112,331,910USD
At 2013-12-3112,236,171USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2014-12-31285,643USD
At 2013-12-31273,092USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2014-12-3118,208USD
At 2013-12-3118,208USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2014-12-311,062,113USD
At 2013-12-31379,164USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2014-10-01 to 2014-12-31-6,844,998USD92
2014-01-01 to 2014-12-31-16,077,468USD365
2014-07-01 to 2014-09-30-6,353,362USD92
2014-04-01 to 2014-06-30-3,718,401USD91
2014-01-01 to 2014-03-31839,293USD90
2013-10-01 to 2013-12-31-2,404,370USD92
2013-01-01 to 2013-12-31-14,320,620USD365
2013-07-01 to 2013-09-30-3,690,955USD92
2013-04-01 to 2013-06-30-3,619,879USD91
2013-01-01 to 2013-03-31-4,605,416USD90
2012-01-01 to 2012-12-31-23,860,127USD366

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-12-315,150,512USD365
2013-01-01 to 2013-12-313,573,893USD365
2012-01-01 to 2012-12-315,929,890USD366

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2014-01-01 to 2014-12-3112,551USD365
2013-01-01 to 2013-12-3111,876USD365
2012-01-01 to 2012-12-3123,662USD366

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2014-01-01 to 2014-12-310USD365
2013-01-01 to 2013-12-310USD365

Inspect the source

Entity
Agile Therapeutics, Inc. / CIK 0001261249
Captured
SEC response SHA-256
dfa60388e3d618cfe1a780836e21d55d8bef6ac848684cf8fd7d6373390ae6f6

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001261249.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))